An examination of the 340B Drug Pricing Program's original intent, current challenges, and potential resolutions in today's complex health care landscape.
David S. Taylor, PharmD, 340B ACE
Advertisement
Articles by David S. Taylor, PharmD, 340B ACE
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Semaglutide Add-On Reduces Glycemic Burden, Cardiometabolic Risk in Older Adults With T2D
2
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
3
New Research Suggests Bempedoic Acid Outperforms Ezetimibe for Heart Health in Patients with Type 2 Diabetes
4
ADA 2026: Why Some T2D Patients Don't Respond to GLP-1 RAs—And What Pharmacists Should Screen For
5